RecruitingNCT06263530
Prognostic Significance of ctDNA in HL
Prognostic Significance of Circulating Tumor DNA in Hodgkin Lymphoma
Sponsor
Interni hematologicka klinika FNKV
Enrollment
500 participants
Start Date
Jan 2, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
Specific somatic mutations using ctDNA will be analyzed in predefined subgroups of cHL (e.g., age \<60 and ≥ 60 years, EBV). These mutations will be correlated with response to the treatment in the first line, in the relapse, during brentuximab vedotin and/or nivolumab treatment. Circulating tumor DNA will be correlated with the extent of tumor mass and chemo/radiotherapy.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Patients ≥ 18 years with newly histologically confirmed classical Hodgkin lymphoma (cHL) will be enrolled
- signing the informed consent
Exclusion Criteria1
- Pacients without signing the informed consent
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06263530
Related Trials
Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)
NCT060881341 location
Colorectal Cancer Dataset in Xijing Hospital From 2011
NCT063083541 location
AI-Assisted System for Accurate Diagnosis and Prognosis of Breast Phyllodes Tumors
NCT062862674 locations